Two patients with eating disorders treated by naltrexone
Language English Country Sweden Media print
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
19855354
PII: NEL300309C05
Knihovny.cz E-resources
- MeSH
- Affect drug effects MeSH
- Alcoholism complications drug therapy MeSH
- Adult MeSH
- Humans MeSH
- Naltrexone therapeutic use MeSH
- Narcotic Antagonists therapeutic use MeSH
- Feeding and Eating Disorders complications drug therapy MeSH
- Self-Assessment MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Naltrexone MeSH
- Narcotic Antagonists MeSH
According to a recent literature review on the opioid mechanism in eating disorders, we found that there is increasing reason to re-examine the treatment potential of naltrexone. The endogenous opioid system belongs to the important modulators of food intake. The eating disorders share many traits with substance dependence models. We present two case histories of time-limited naltrexone therapy to show that, in clinical practice, individualized indication may contribute to short-term improvement and to prediction of a different long-term treatment outcome.
Convergent dysregulation of frontal cortical cognitive and reward systems in eating disorders
